Intelligence · Clinical Development
Pipeline search results
Programs matching “treatment” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 270 pipeline programs matching "treatment" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
An open-label for inteneded for treatment of - ac…
Lacuna Pharma Pty Ltd
inteneded for treatment of - active rheumatoid arthritis in adult patients, - polyarthritic forms of severe, active juvenile idiopathic arthritis, when the response to nonsteroidal anti-inflammatory drugs has been inadequate, - severe recalcitrant disabling psoriasis which is not adequately responsive to other forms of therapy and severe psoriatic arthritis in adult patients, - mild-to-moderate Crohn’s disease, either alone or in combination with corticosteroids, in adult patients refractory or intolerant to thiopurines.
1 trial -
BS-02
Blue Earth Diagnostics Ireland Ltd
Treatment of human papilloma virus (HPV) associated infections, precancers and cancers
1 trial -
BS-03
Blue Earth Diagnostics Ireland Ltd
Treatment of human papilloma virus (HPV) associated infections and cancers
1 trial -
Bioequivalence of Cladribine 10 mg from two different products
Lacuna Pharma Pty Ltd
No therapeutic indication in the current trial with healthy volunteers. The intended indication is for treatment of adult patients with highly active relapsing multiple sclerosis (MS).
1 trial -
CAR-T Re-treatment
Nanjing Legend Biotech Co.
Multiple Myeloma
1 trial -
CAR123 T cell treatment of relapsed/refractory hematologic malignancies.
The George Institute
Relapsed/refractory CD123+ hematological malignancies: Acute Myeloid Leukemia, Myelodysplastic Syndrome, Blastic Plasmacytoid Dendritic Cell Neoplasm, Acute Lymphoblastic Leukemia.
1 trial -
CLN-978-RA-101
Cullinan Therapeutics
Treatment-Refractory Rheumatoid Arthritis
1 trial -
DS3201-324
Daiichi Sankyo
This study will be a Phase 1b, global, multicenter, open-label, 2-part study of valemetostat in combination with DXd ADCs. The Master Protocol study design contains independent subprotocols, which have been defined by treatment combination and subject population, as follows: Sub-protocol A: Valemetostat in combination with T-DXd in subjects with previously treated, unresectable and/or metastatic HER2-low (immunohistochemistry[IHC] 1+ or IHC 2+/in situ hybridization [ISH]-negative) BC; for details, see Sub-protocol A. Sub-protocol B: Valemetostat in combination with T-DXd in subjects with previously treated, advanced or metastatic HER2-positive gastric or GEJ adenocarcinoma; for details, see Sub-protocol B. Sub-protocol C: Valemetostat in combination with Dato-DXd in subjects with previously treated, locally advanced, unresectable, or metastatic non-squamous NSCLC with or without actionable genomic alteration(s); for details, see Sub-protocol C.
1 trial -
FYB206-C1-01
Formycon AG
Melanoma: Adjuvant treatment of patients with Stage IIB, IIC, or III melanoma following complete resection
1 trial -
GRoningen Early-PD Ambroxol Treatment Pharmacokinetics
Disc Medicine
Parkinson's disease
1 trial -
HP7040-01
Gruenenthal GmbH
Treatment of pain
1 trial -
HS-10345 84mg
Jian Li
Treatment Resistant Depressive Disorder
1 trial -
INCB 57643-103
Incyte
Treatment of participants with MF, MDS, ET, or MDS/MPN
1 trial -
INSIGHT
The George Institute
Histologically confirmed locally advanced or metastatic solid tumor (Strata A, B, D): Specification for Stratum C: Only patients with NSCLC adenocarcinomas, (squamous or adenosquamous not permitted) who are scheduled to receive platin + pembrolizumab + pemetrexed standard treatment (only for Stratum C) Specification for Stratum E: Including only metastatic or irresectable locally advanced urothelial carcinomas (only for Stratum E)
1 trial -
Miricorilant Treatment A
CORCEPT THERAPEUTICS INC
Healthy
1 trial -
NL85300.041.23
Disc Medicine
Metastatic or unresectable solid malignancies. Standard of care treatment options must not be available or not be considered feasible. Patients must have a primary tumor or metastasis that is suitable for HIFU-HT treatment.
1 trial -
NN6706-8230
NovoThirteen
Healthy volunteers, treatment for heart failure
1 trial -
NN7442-7582
NovoThirteen
Prophylaxis and on-demand treatment respectively in patients with haemophilia A with or without FVIII inhibitors.
1 trial -
PBTC-051
Pyxis Oncology
Glioblastoma Multiforme
1 trial -
PH-ACP3GA-01/24
Philogen S.p.A.
Patients with prostate cancer with: -suspected metastasis who are candidates for initial definitive therapy -suspected recurrence based on elevated serum prostate-specific antigen (PSA) level (i.e., a progressive and confirmed serum PSA level > 0.2 ng/mL) -metastatic disease who might be candidates for treatment with 177Lu-labelled PSMA ligands
1 trial -
PH-ACP3GA-03/25
Philogen S.p.A.
Patients with prostate cancer with: - suspected metastasis who are candidates for initial definitive therapy - suspected recurrence based on elevated serum prostate-specific antigen (PSA) level (i.e., a progressive and confirmed serum PSA level > 0.2 ng/mL) - metastatic disease who might be candidates for treatment with 177Lu-labelled PSMA ligands
1 trial -
PH-F8IL10INTRA-03/24
Philogen S.p.A.
Patients with Rheumatoid Arthritis (RA) who, despite treatment with stable doses (for at least 3 months) of disease-modifying antirheumatic drugs (DMARDs, conventional, biologic and/or targeted synthetic), present arthritis flare(s) suitable for intra-articular (IA) injection in a knee, shoulder, ankle, wrist or elbow.
1 trial -
Pharmacokinetic study of colistimethate sodium
Zaklady FarmaFarmaceutyczne Polpharma S.Aceutyczne Polpharma S.A.
serious infections caused by selected aerobic gram-negative pathogens in patients with limited treatment options
1 trial -
Placebo for Treatment A
Agios Netherlands B.V.
Healthy Volunteers
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.